Anna K. Abram

No Appeal Of LDT Decision Means Ball Is Back In FDA's Court For Policy Clarification

Five FDA Takeaways From The FY26 Budget

MAHA Commission Report On Children's Health Takes Aim At Ultra-Processed Foods And Medication Practices, Among Other Targets

The Trump Administration Continues Focus On Drug Pricing With "Most-Favored-Nation Prescription Drug Pricing" Executive Order

The Trump Administration Seeks To Spur Domestic Drug Manufacturing With Regulatory Relief EO

The Trump Administration Turns To Drug Pricing: Key Actions And Timelines Under The New EO

District Court Vacates FDA LDT Rule; What's Next For Regulation Of Lab Testing?

HHS, FDA Announce Multiple Initiatives On Food Safety, Quality And Compliance Fronts

"MAHA" Picks Up Momentum With The President's Make America Healthy Again Commission

2025 Perspectives In Private Equity: Health Care & Life Sciences